Symphogen A/S, a private biopharmaceutical company with leadership in
recombinant antibody mixtures for therapeutic use, today announced the
relocation of its corporate headquarters in Lyngby, outside Copenhagen,
Denmark, to a 10,000 m2 (100,000 ft2) facility in
Ballerup, also a suburb of Copenhagen. Separately, Symphogen announced
that Mads Laustsen was appointed to the newly created position of Chief
Mads Laustsen, one of the founders of CMC Biologics, served as the
company's CEO from the time of the company's inception 2001 until May
2011, when he was named to the Board of Directors. During this period,
the company grew from a business idea to a global leader in contract
biologics manufacturing. Laustsen joins Symphogen June 1, but remains a
non-executive Director on the CMC Biologics Board. Prior to establishing
CMC Biologics, he spent 16 years developing and manufacturing bulk
enzymes and biopharmaceuticals at Novo Nordisk, Zymogenetics, and
Novozymes. Laustsen has served as member of various advisory boards,
has been active in development of new process technologies, and holds
numerous patents in the field.
Laustsen commented: "Symphogen's antibody mixtures are at the forefront
of a new generation of therapeutic options for cancer patients. Equally
as important, Symphogen has pioneered manufacturing processes that few
believed were possible, and demonstrated capabilities and efficiencies
that are now ready to advance to a much larger scale. Clearly, the
company is at a crossroads in its development, and I look forward to
joining its accomplished leadership team."
Chief Executive Officer of Symphogen, Kirsten Drejer, PhD, commented:
"Mads Laustsen adds extensive manufacturing experience to Symphogen's
experienced Executive Management Team, and will help transform Symphogen
from a company focused on R&D to an integrated business organization
with in-house antibody production capabilities."
About Symphogen A/S
Symphogen is developing next-generation antibody therapeutics for the
treatment of cancer and is dedicated to bringing truly innovative
oncology products to the market.
The company has advanced the frontier of antibody discovery by creating
well-characterized antibody mixtures that address multiple oncology
targets in a single drug product. The company has matured its oncology
pipeline and has currently brought two product candidates into the
clinic. The company's productive technology suite - capable of
identifying, selecting, and manufacturing optimal antibody mixtures -
fuels Symphogen's innovative pipeline.
The lead oncology product, Sym004, was out-licensed to Merck KGaA in
2012 following phase 2 clinical data in late stage cancer patients.
In total, the company has raised €249 million in equity capital from
premier international investors including Novo, Essex Woodlands Health
Ventures, and PKA, and employs 100 people, most of whom are based at
Symphogen's facilities in Copenhagen.
[ Back To NFVZone's Homepage ]